Cholestasis in Extreme Low Birth Weight Infants (ELBW)

Status Completed

Clinical Trial Summary

Parenteral nutrition associated liver disease (PNALD) in preterm neonates is characterized by early occurrence of intrahepatic cholestasis (parenteral nutrition associated cholestasis (PNAC).

Extreme low birth weight infants (ELBW, birth weight < 1000 g) are at increased risk for development of PNAC.

Important factors implicated in the aetiology of PNAC are high caloric parenteral nutrition using amino acids or dextrose, but also intravenous lipids and infections in particular necrotizing enterocolitis (NEC).

Due to a change of paradigm a more aggressive nutrition with early use of parenteral amino acids/lipids and early fortification of mothers milk or alternatively high caloric preterm formula is warranted. Accordingly - in line with the existing expert opinion and evidence - the feeding policy at the neonatal care units of our hospital was adapted.

Evidence exists that PNAC might be caused by the use of high concentrations of amino acids and lipids in parenteral nutrition. Furthermore NEC is associated with high osmotic feeds. Therefore the incidence of PNAC might be increased directly and indirectly after introducing the new feeding policy.

The investigators therefore aim at retrospectively investigating the incidence of PNAC before and after introduction of a feeding policy of "aggressive nutrition" for ELBW infants.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01164878
Study type	Observational
Source	Medical University of Vienna
Contact
Status	Completed
Phase	N/A
Start date	January 2010
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04510090` - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus	Phase 1
Completed	`NCT02917408` - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Completed	`NCT00738101` - Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants	N/A
Completed	`NCT00004414` - Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis	N/A
Completed	`NCT03662282` - Omegaven as Alternative Parenteral Fat Nutrition	Phase 3
Recruiting	`NCT02334293` - Omegaven® as Parenteral Nutrition	N/A
Recruiting	`NCT01252043` - Retrospective Review of CT and MR in Pediatric Patients With Cholestasis	N/A
Completed	`NCT00846963` - Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates	Phase 2/Phase 3
Completed	`NCT00007033` - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease	N/A
Completed	`NCT01194063` - Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children	Phase 3
Recruiting	`NCT01998620` - Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis	Phase 4
Completed	`NCT00080236` - Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation	Phase 2
Completed	`NCT00058890` - Gabapentin to Treat Itch in Patients With Liver Disease	Phase 3
Active, not recruiting	`NCT00004315` - Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease	Phase 2
Active, not recruiting	`NCT02922751` - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed	`NCT04604652` - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis	Phase 2
Terminated	`NCT02267707` - Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia	Phase 1
Completed	`NCT02357576` - Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD	Phase 3
Completed	`NCT02721277` - SMOFlipid to Lessen the Severity of Neonatal Cholestasis	Phase 1/Phase 2
Terminated	`NCT02767648` - Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region	N/A